13 Feb 2021 | Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution agreement with Korea's Prestige...
05 Jan 21 | EU | The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium found strong uptake of Amgen’s Kanjinti (biosimilar trastuzumab) in Europe.
08 Jan 21 | A new study reviewed the use of rituximab as an alternative treatment option for the management of multiple sclerosis (MS). While not approved for MS, there is evidence of significant off-label usage of rituximab for the treatment of MS in some Northern European countries.
Get our Pearce IP Blogs & BioBlast™ sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast™ to recieve our updates via email.